Study Shows Actos Increases Risk of Bladder Cancer
A new meta-analysis of existing studies on Actos and bladder cancer published in the Diabetes Research and Clinical Practice Journal found an increased risk of bladder cancer.
The new meta-analysis follows a British Medical Journal study finding that Actos increases the risk of bladder cancer. The meta-analysis examined five studies with a total of over 2,350,000 patients. The result of the study included findings that Actos can “significantly increased risk of bladder cancer in patients with diabetes.”
Thompson & Tredennick partner Joel Thompson comments, “This comprehensive, in-depth study simply confirms what we have feared for some time. Individuals suffering from Type II Diabetes, who are taking Actos, should immediately consult their physician in order to determine whether or not they should continue.”
Nick Bruno is a Legal Assistant at Thompson & Tredennick